beta-adrenergic receptor Agonists
19 drugsAbout beta-adrenergic receptor
The beta-adrenergic receptor (β-adrenergic receptor) is a GPCR mediating catecholamine effects, influencing heart rate, bronchodilation, and metabolism.
Human genetics strongly support beta-adrenergic receptor targeting, with hypertension (score 0.89), essential hypertension (0.83), and cardiovascular disease (0.79) associations. Loss-of-function variants are protective, suggesting inhibition is beneficial.
Nineteen small molecule drugs target beta-adrenergic receptors, including ADRENALIN, COREG, and NEFFY, spanning 'other' indications (15), cardiovascular (2), and ophthalmology (2).
Strategic Insights
ℹ️ How we calculate- White space opportunity in HIV Infections with only 4 trials.
Human Genetic Evidence Strong
Strong genetic evidence supports ADRB1's role in hypertension and cardiovascular disease.
High genetic scores suggest clinical trials targeting hypertension have increased likelihood of success.
💡 Why inhibition?
- • Loss-of-function variants reduce disease risk (OR < 1)
- • 100% directional consistency across 3 traits
- • Strong signal in cardiovascular disease, phenotype pathways
Cross-Disease Effects
Trade-off: LowDirection of Effect
100% alignedEvidence Across Diseases
9 totalGWAS and other genetic studies link ADRB1 to 9 diseases.
Inhibiting this target may be therapeutic
Inhibiting this target may be therapeutic
🔗 Colocalization Evidence 20 strong
max H4: 1.00eQTL/pQTL signals for ADRB1 colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top Drugs
Sixteen companies have approved beta-adrenergic receptor drugs, including GLENMARK PHARMS LTD and ADAMIS PHARMS CORP.
A fragmented market suggests moderate entry barriers, but established players have an advantage.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| NEFFY | ARS PHARMS OPERATION | 2024 | 2 |
| BRIMONIDINE TARTRATE AND TIMOLOL MALEATE | CAPLIN | 2022 | 2 |
| ADRENACLICK | IMPAX | 2003 | 2 |
| XYLOCAINE W/ EPINEPHRINE | Fresenius Kabi | 1948 | 2 |
| EPINEPHRINE (AUTOINJECTOR) | Teva | 2018 | 2 |
| COMBIGAN | AbbVie | 2007 | 2 |
| EPIPEN | Viatris | 1987 | 2 |
| EPIPEN JR. | Viatris | 1987 | 2 |
| SYMJEPI | ADAMIS PHARMS CORP | 2017 | 2 |
| EMERPHED | NEXUS | 2020 | 1 |
| NOREPINEPHRINE BITARTRATE | RISING | 2003 | 1 |
| LEVOPHED | Pfizer | 1950 | 1 |
| NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE | LONG GROVE PHARMS | 2021 | 1 |
| AKOVAZ | EXELA PHARMA | 2016 | 1 |
| NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | SAGENT | 2021 | 1 |
| CORPHEDRA | PH HEALTH | 2017 | 1 |
Drug Modality Landscape
Modalities
Routes of Administration
beta-adrenergic receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides may offer differentiation opportunities.
Clinical Trials 753 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 117 | 81 | 17 | 17 | 83% |
| Phase 2 | 164 | 100 | 22 | 40 | 82% |
| Phase 3 | 160 | 109 | 14 | 35 | 89% |
| Phase 4 | 312 | 217 | 32 | 58 | 87% |
Top Sponsors
By Modality
Top Conditions
Drug Approval Timeline (1948 - 2024)
Approvals span 77 years from 1948 (XYLOCAINE W/ EPINEPHRINE) to 2024 (NEFFY).
Consistent approvals indicate sustained interest, but recent approvals may signal renewed focus.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 17 companies competing
- • Market share by company
Full Drug Portfolio
- • All 19 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 19-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 7 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 494 clinical trials targeting beta-adrenergic receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities